157 related articles for article (PubMed ID: 21057818)
1. [The fine line between innovation and risk : Is anti-NGF a pain medication of the future?].
Schaible HG
Schmerz; 2010 Dec; 24(6):559-60. PubMed ID: 21057818
[No Abstract] [Full Text] [Related]
2. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor.
Eibl JK; Strasser BC; Ross GM
Neurochem Int; 2012 Dec; 61(8):1266-75. PubMed ID: 23103525
[TBL] [Abstract][Full Text] [Related]
3. Targeting nerve growth factor in pain: what is the therapeutic potential?
Watson JJ; Allen SJ; Dawbarn D
BioDrugs; 2008; 22(6):349-59. PubMed ID: 18998753
[TBL] [Abstract][Full Text] [Related]
4. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?
Bannwarth B; Kostine M
Drugs; 2014 Apr; 74(6):619-26. PubMed ID: 24691709
[TBL] [Abstract][Full Text] [Related]
5. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain.
Miller RE; Malfait AM; Block JA
Clin Exp Rheumatol; 2017; 35 Suppl 107(5):85-87. PubMed ID: 28967370
[TBL] [Abstract][Full Text] [Related]
6. Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
Bannwarth B; Kostine M
Drugs; 2017 Sep; 77(13):1377-1387. PubMed ID: 28660479
[TBL] [Abstract][Full Text] [Related]
7. Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs.
Cao Z; Zhou J; Long Z; Li Y; Sun J; Luo Y; Wang W
Aging (Albany NY); 2020 Dec; 13(1):1051-1070. PubMed ID: 33293475
[TBL] [Abstract][Full Text] [Related]
8. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?
Miller RE; Block JA; Malfait AM
Curr Opin Rheumatol; 2017 Jan; 29(1):110-118. PubMed ID: 27672741
[TBL] [Abstract][Full Text] [Related]
9. Nerve growth factor: an update on the science and therapy.
Seidel MF; Wise BL; Lane NE
Osteoarthritis Cartilage; 2013 Sep; 21(9):1223-8. PubMed ID: 23973134
[TBL] [Abstract][Full Text] [Related]
10. Nerve growth factor and nociception: from experimental embryology to new analgesic therapy.
Lewin GR; Lechner SG; Smith ES
Handb Exp Pharmacol; 2014; 220():251-82. PubMed ID: 24668476
[TBL] [Abstract][Full Text] [Related]
11. Imaging atlas for eligibility and on-study safety of potential joint adverse events in anti-NGF studies.
Roemer FW; Guermazi A
Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S1-2. PubMed ID: 25527215
[No Abstract] [Full Text] [Related]
12. NGF and GDNF differentially regulate TRPV1 expression that contributes to development of inflammatory thermal hyperalgesia.
Amaya F; Shimosato G; Nagano M; Ueda M; Hashimoto S; Tanaka Y; Suzuki H; Tanaka M
Eur J Neurosci; 2004 Nov; 20(9):2303-10. PubMed ID: 15525272
[TBL] [Abstract][Full Text] [Related]
13. The current status of imaging in anti-NGF clinical trials.
Miller CG; Guermazi A; Roemer F
Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S3-7. PubMed ID: 25527218
[No Abstract] [Full Text] [Related]
14. Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management.
McKelvey L; Shorten GD; O'Keeffe GW
J Neurochem; 2013 Feb; 124(3):276-89. PubMed ID: 23157347
[TBL] [Abstract][Full Text] [Related]
15. The evolution of nerve growth factor inhibition in clinical medicine.
Wise BL; Seidel MF; Lane NE
Nat Rev Rheumatol; 2021 Jan; 17(1):34-46. PubMed ID: 33219344
[TBL] [Abstract][Full Text] [Related]
16. Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis.
Ishikawa G; Koya Y; Tanaka H; Nagakura Y
Osteoarthritis Cartilage; 2015 Jun; 23(6):925-32. PubMed ID: 25677108
[TBL] [Abstract][Full Text] [Related]
17. Imaging atlas for eligibility and on-study safety of potential hip adverse events in anti-NGF studies (Part 2).
Roemer FW; Hayes CW; Miller CG; Hoover K; Guermazi A
Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S43-58. PubMed ID: 25527219
[TBL] [Abstract][Full Text] [Related]
18. A tale of two TrkA inhibitor trials: same target, divergent results.
Walsh DA; Neogi T
Osteoarthritis Cartilage; 2019 Nov; 27(11):1575-1577. PubMed ID: 31356877
[No Abstract] [Full Text] [Related]
19. Local Administration of Low-Dose Nerve Growth Factor Antibody Reduced Pain in a Rat Osteoarthritis Model.
Tian Y; Onodera T; Terkawi MA; Iwasaki K; Hishimura R; Liang D; Miyazaki T; Iwasaki N
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806315
[TBL] [Abstract][Full Text] [Related]
20. Tanezumab in the treatment of chronic musculoskeletal conditions.
Jayabalan P; Schnitzer TJ
Expert Opin Biol Ther; 2017 Feb; 17(2):245-254. PubMed ID: 27936977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
